Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review

Table 2 Baseline total patient number, number of male patients, mean age, body mass index and ethnicity for the 8 included studies

Ref.	Patients		Mean age	BMI	Ethnicity
	Males	Total (n)	(yr)	(kg/m2)	Caucasian	African American	Asian
Apolinario et al[9]	40	63	41 (± 9.3)5	Information not provided	Information not provided6
1Lagging et al[34]	169	2522			2529
IL28B rs12979860 CC	64	93	41.6 (± 10.1)5	25.1 (± 3.6)5
IL28B rs12979860 CT	77	123	41.9 (± 9.5)5	25.0 (± 3.5)5
IL28B rs12979860 TT	28	36	41.9 (± 11.4)5	25.0 (± 3.5)5
Diago et al[7]	77	137	42 (± 9.7)5	Information not provided	Information not provided
Fattovich et al[21]	133	2263	46 (± 11)5	24.7 (± 3.8)5	226
Kurelac et al[33]	17	46	41.5 (± 12.4)5	23.7 (21.9-25)4	46
Darling et al[31]	176	272	48.4 (± 7.4)5	Information not provided	138	134
Darbala et al[32]	144	159	46.47 (± 8.83)5	30.18 (± 5.05)5	Information not provided7
Al-Ashgar et al[19]	41	64	38.7 (± 11.5)5	Information not provided	Information not provided8

¹Study did not provide baseline characteristics for their entire population, but instead provided baseline demographics in accordance with IL-28 genotype (only baseline characteristics for rs12979860 are reported in the review, as these were representative for the study population);

²253 was reported to be enrolled, however when adding the males and female patients, it sums to 252;

³Only 226 out of 280 patients had serum available for iP-10 testing;

⁴Median (25-75 percentiles);

⁵Mean (SD);

⁶51 patients from clinical trials had Spanish nationality;

⁷Egyptian nationality;

⁸Saudi nationality;

⁹95% of the original DITTO patient population were Caucasian. BMI: Body mass index.